In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...
TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...
The data from the CDC's National Immunization Survey estimates that 37.6% of Americans ages 65 and older had gotten a shot of ...
Health agencies, counties and state officials have been resisting efforts to provide booster jabs to Americans this fall.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback